Abstract: New formulations of spiramycin suitable for oral administration, particularly for children, comprise spiramycin and potassium acesulfame. These formulations mask the bitterness of spiramycin without adversely affecting the bioavailability or stability of the spiramycin. Preparation by wet granulation followed by dry state mixing is also disclosed.
Abstract: The invention discloses nanoparticles offering an extended time before capture by the reticulo-endothelial system. Said particles are composed of an ethylene and/or propylene polyoxide polylactic copolymer optionally mixed with a polylactic polymer.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
November 4, 1997
Assignee:
Rhone-Poulenc Rorer S.A.
Inventors:
Gilles Spenlehauer, Didier Bazile, Michel Veillard, Christian Prud'Homme, Jean-Paul Michalon
Abstract: A medicament compact is produced by placing loose powdered medicament in a mould having a longitudinal axis where a mandrel is positioned along the longitudinal axis of the mould compressing the medicament when a force parallel to the longitudinal axis is applied. The frictional force between the medicament and the mould and the frictional force between the medicament and the mandrel are opposite.
Type:
Grant
Filed:
June 17, 1996
Date of Patent:
September 23, 1997
Assignee:
Fisons plc
Inventors:
Clive Roland Sleath, Paul Manuel Anson, Hugh William Dyson
Abstract: Stable, pharmaceutical ketoprofen salts for oral administration are provided in oily solutions to avoid direct contact of acid forms of ketoprofen with the gastric or duodenal mucus membranes. Sodium, arginine, lysine and/or N-methylglucamine salts of ketoprofen are disclosed in solutions of polyoxyethyenatide vegetable oil, castor oil, esters of fatty acids and/or polyols. These oily solutions of ketoprofen may be administered orally in capsule form.
Abstract: An inhaler for inhaling pulverulent medicament from within a capsule comprises a chamber (24) within which the capsule is free to rotate while having its longitudinal axis in the median plane of the chamber and thus generally parallel to the front and rear walls (30) and (31) of the chamber, by virtue of the fact that the spacing between said front and rear walls is less than the axial length of the capsule but just greater than the diameter of the capsule. The device includes pins (21) serving as opening means to pierce the ends of the capsule while it is seated in a recess (25), whereupon the retraction of the pins (21) allows the capsule to be entrained into swirling airflow in the chamber (24) during inhalation of air through air inlets (26) and out through a mouthpiece nozzle (27).
Type:
Grant
Filed:
February 16, 1993
Date of Patent:
June 4, 1996
Assignee:
Rhone-Poulenc Rorer Ltd.
Inventors:
John R. Calvert, Robert S. Cook, Michael A. Hobbs, Ann-Marie Leighton, Gordon T. Simpkin, Roy Trunley, Anthony D. West
Abstract: The present invention relates to a pharmaceutical form based on cephalosporin. It relates in particularly to a tabletted pharmaceutical form.
Abstract: In a method in which an ionizable pharmaceutical material, such as theophylline, having a pharmaceutically-active anionic group is bonded to an anion exchange resin having cationic groups bonded to displacable anionic groups by bringing said material and said resin into contact with each other under conditions such that the pharmaceutically-active anionic group of said material is bonded to the cationic group of said resin and replaces the anionic group thereof, the improvement comprising effecting said contact in an environment which is substantially free of carbon dioxide and/or bicarbonate ion, a pharmacologically active composition comprising said pharmaceutically active anion and said resin, including a composition in which at least about 40% of the binding capacity of the resin comprises said pharmaceutically active anion, and a sustained release pharmaceutical composition, including enteric coated particles of the composition, and stabilizing said composition by maintaining it in an environment substan
Type:
Grant
Filed:
November 10, 1992
Date of Patent:
May 9, 1995
Assignee:
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Abstract: Formulations of spiramycin granules may be conducted by preparing a solution of albumin in the presence of an antifoaming agent, separately preparing a suspension of spiramycin in the presence of an antifoaming agent, granulating and drying a mixture of one or more sugars and water, mixing the albumin solution and spiramycin suspension with heating to coagulate the albumin, evaporating the solvents to obtain spiramycin granules, and mixing the sugar granules and spiramycin granules. Oral spiramycin formulations prepared according to this method are also disclosed.
Type:
Grant
Filed:
July 16, 1993
Date of Patent:
April 4, 1995
Assignee:
Rhone-Poulenc Rorer S.A.
Inventors:
Ana Calvo, Luis A. Del Rio, Manuel Esteban, Robert Rona
Abstract: Thioformamide compounds of formula (I) are disclosed in which R is alkyl, Y is methylene, ethylene or a direct bond, A is optionally substituted phenyl or pyridyl, R.sup.1 is hydrogen and R.sup.2 is N-alkylsulphonyl-, N-phenylsulphonyl-N'-alkylamidino or an arylsulphonyl group; R.sup.1 and R.sup.2 may both independently represent alkyl- or arylsulphonyl groups.